EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hidradenitis suppurativa, from basic science to surgery and a new era of tailored targeted therapy: An expert opinion paper

Angelo Valerio Marzano, Michele Bartoletti, Vincenzo Bettoli, Luca Bianchi, Andrea Chiricozzi, Mario Clerici, Paolo Dapavo, Valentina Dini, Caterina Foti, Cristina Magnoni, Matteo Megna, Giuseppe Micali und 2 weitere

Archives of Dermatological Research · 2025

DOI: 10.1007/s00403-025-04016-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archives of Dermatological Research, 2025. Verfasst von Angelo Valerio Marzano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. angelo.marzano@unimi.it. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Delayed Diagnosis, Time-to-Treatment, Molecular Targeted Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Milano.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterised by an aberrant activation of innate immunity and increased production of pro-inflammatory mediators such as interleukin 17 (IL-17). IL-17 has been shown to play a key role in the pathogenesis of HS and evidence highlights the potential of IL-17-targeted therapies. The fully human IgG/κ monoclonal antibody secukinumab, which specifically targets IL-17A and inhibits interaction with its receptor, has recently been approved for the treatment of moderate-to-severe HS. Secukinumab offers patients an efficacious and well-tolerated treatment option in terms of sustained response by rapidly improving signs and symptoms, and preventing disease progression in the absence of loss of response. Being a challenging disease, HS is associated with a delay to diagnosis of 3–10 years and, consequently, late implementation of appropriate treatment, leading to disease progression. Misdiagnosis due to flawed understanding and lack of awareness among medical providers and patients is considered an important factor contributing to the delayed diagnosis. Thus, serious efforts must be made on a large scale to urgently reduce the delay in HS diagnosis and reduce the disease burden in patients, including raising awareness, implementation of education programmes at medical and specialisation schools, as well as continuous education of healthcare providers at different levels for the early detection of HS and initiation of appropriate treatment. Here, we present the main critical unmet needs in the diagnosis and treatment of patients affected by HS, address how disease awareness and comprehensive multidisciplinary management (offering both medical and surgical care) can benefit patients, and suggest therapeutic options, based on clinical characterisation and early identification and intervention (window of opportunity), to be adopted for a timely and better management of disease progression and to fill current gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaDelayed DiagnosisTime-to-TreatmentMolecular Targeted TherapyHumansAntibodies, Monoclonal, HumanizedPatient Care TeamCost of IllnessDisease ProgressionInterleukin-17

Stichwörter der Autor:innen

Hidradenitis suppurativaInterleukin 17SecukinumabTargeted therapyUnmet needs

Substanzen

secukinumabAntibodies, Monoclonal, HumanizedIL17A protein, humanInterleukin-17

Autor:innen und Institutionen

  • Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. angelo.marzano@unimi.it.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. angelo.marzano@unimi.it.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Infectious Disease Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • O.U. Of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
  • Dermatology, Fondazione Policlinico Tor Vergata, Department of Systems Medicine, Tor Vergata University, Rome, Italy.

Förderung

  • Università degli Studi di Milano

Zitieren

APA

Marzano, A. V., Bartoletti, M., Bettoli, V., Bianchi, L., Chiricozzi, A., Clerici, M., Dapavo, P., Dini, V., Foti, C., Magnoni, C., Megna, M., Micali, G., Molinelli, E., & Prignano, F. (2025). Hidradenitis suppurativa, from basic science to surgery and a new era of tailored targeted therapy: An expert opinion paper. Archives of Dermatological Research. https://doi.org/10.1007/s00403-025-04016-1

Vancouver

Marzano AV, Bartoletti M, Bettoli V, Bianchi L, Chiricozzi A, Clerici M, et al. Hidradenitis suppurativa, from basic science to surgery and a new era of tailored targeted therapy: An expert opinion paper. Archives of Dermatological Research. 2025. doi:10.1007/s00403-025-04016-1

BibTeX
@article{Marzano2025,
  author = {Marzano, Angelo Valerio and Bartoletti, Michele and Bettoli, Vincenzo and Bianchi, Luca and Chiricozzi, Andrea and Clerici, Mario and Dapavo, Paolo and Dini, Valentina and Foti, Caterina and Magnoni, Cristina and Megna, Matteo and Micali, Giuseppe and Molinelli, Elisa and Prignano, Francesca},
  title = {Hidradenitis suppurativa, from basic science to surgery and a new era of tailored targeted therapy: An expert opinion paper},
  journal = {Archives of Dermatological Research},
  year = {2025},
  doi = {10.1007/s00403-025-04016-1}
}
Kostenlos starten →